On Oct. 25, the U.S. Food and Drug Administration (FDA) announced a recall for two lots of Quinapril and Hydrochlorothiazide Tablets, USP 20mg/12.5mg by the drug manufacturer Aurobindo Pharma USA, Inc., due to a detection of Nitrosamine Drug Substance Related Impurity.

Quinapril and Hydrochlorothiazide Tablets, USP are fixed-combination tablets used for the treatment of hypertension. At this time, there are no reports of adverse effects related to this recall.

For more information and recommendations, visit the FDA webpage.

Clinical Topics: Statins

Keywords: ACC Advocacy, Quinapril, Antihypertensive Agents, United States Food and Drug Administration, Hydrochlorothiazide, Tablets, Nitrosamines

< Back to Listings